I found the atmosphere at the JP Morgan and surrounding conferences very upbeat this year. Most notably the idea of a single asset financing is coming to the fore, and the middle East is getting the attention it deserves with the large patient population served in the MENA region.
There seems to be a willingness on the part of non profit organizations and foundations to come to the table and see what can be used compassionately in the growing global market. This was heartening to me, as diabetes grows globally and other unmet needs are being served by companies such as PATH.
Roche wins the prize for the most M&A’s truly laying a foundation for growth in genomics and diagnostics.
The surprise was the appearance of FinTECH, (Financial Technology) which has the potential to reshape private equity investing, as Venture investing goes increasingly to later stage. As long as there is good science being done, there will be financiers willing to help it along.
Behold the turtle, she never makes any progress until she sticks her neck out.
Sticking my neck out for new technology, software for breast screening, which looks at the breast as an organ.
First Warning Systems
The signal of taxene, not the drug cures as well when applied directly through the system developed by Nativis, Inc
NIH unit sets aside $461M for genome sequencing project
The National Human Genome Research Institute has announced it will devote $461 million to projects that will help integrate DNA sequencing into mainstream medicine. A majority of the support, beginning at $86 million annually, will go to existing projects at three sequencing centers that were involved in the Human Genome Project. Some of the money will be used to establish projects dealing with the genetic basis of Mendelian illnesses and the effects of clinical sequencing. Nature
“There is a call today for dramatic change to move from traditional governance to concrete performance. Companies and investors should recognize firms have multiple constituencies and many types of investors, and the should seek to balance the interests in accordance with their influence on the corporation’s long term success.
Directors should seek to go beyond mere compliance and add value to the corporation.
A core responsibility is to demonstrate greater board engagement with management in the development of strategy, oversight of risk, approval of executive compensation, and transparency.
I recently read an article which said, to no surprise, that the biotech field was no different than other career paths for women, meaning there were few women at the top. This has not been the case in my career as I was the first analyst, not the first woman analyst, for biotechnology and one of the very first consultants to venture capitalists about biotechnology. Many good women followed in my footsteps, and when I started Sequenom, there were few women CEO’s but I did not find that to hinder my fund raising or recruitment. The biotech field has and still does recognize abilities over gender so women step up.
I predicted in the early 1980’s that the engine that was created then would become the pharma of the future. The prediction has become reality, as most of the early biotech companies formed in the 1970-80’s now have names like Roche, Novartis, and Amgen one of the remaining originals has a market cap equal to Pfizer. The next next new thing is Synthetic Biology